Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.59 |
| ▸ | HTR7 | P34969 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658017 | 0.94 | HTR7 (0.58) | HTR1AHTR7LMNATSHRRAB9A | |
| SCHEMBL5657837 | 0.91 | HTR1A (0.56) | HTR1AHTR7LMNATSHRRAB9A | |
| SCHEMBL5657971 | 0.90 | KCNH2 (0.50) | HTR1AHTR7LMNATSHRRAB9A | |
| SCHEMBL5656134 | 0.90 | HTR1A (0.48) | HTR1AHTR7LMNATSHRRAB9A | |
| SCHEMBL5659352 | 0.90 | HTR1A (0.49) | HTR1AHTR7TSHRNPSR1MAPT | |
| SCHEMBL5655713 | 0.90 | MEN1 (0.57) | HTR1AHTR7LMNATSHRKMT2A | |
| SCHEMBL5656201 | 0.89 | HTR1A (0.55) | HTR1AHTR7KMT2AMEN1MAPT | |
| SCHEMBL5656238 | 0.86 | HTR7 (0.53) | HTR1AHTR7LMNAKMT2AMEN1 | |
| SCHEMBL5656230 | 0.86 | HTR7 (0.53) | HTR1AHTR7LMNAKMT2AMEN1 | |
| SCHEMBL5654667 | 0.86 | HTR7 (0.53) | HTR1AHTR7MAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | HTR1A 8/4885HTR7 13/4885LMNA 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.